Fig. 4From: Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group RegistryOS 2nd line sunitinib by start year. The Gehan–Breslow–Wilcoxon test gives more weight to early time points and appears to be more appropriate for this analysis because patients in the Start year < 2006 category that live long enough will have increased access to ≥ 3L drugs and thus potential for increased OSBack to article page